With the news of EUA approval by the FDA for at-home, non-prescription COVID test kits granted to Ellume and Abbott, the QXD team wanted to assure you that we are staying the course!

We anticipated competition; here is a direct quote from Dr. Maria Nagy, Ph.D., CEO/Founder of Quorum X Diagnostics:

"This is a global market and a global need. Yes, the roads may get a bit choppy moving forward but we will prevail. We have a superior team and a superior product. Zig Ziggler says, 'Success is predictable' and I believe, for us, it's inevitable. So, hold on and enjoy the ride! It will be a wild one, but I am confident we will prevail. Quorum X Diagnostics will succeed. If your confidence wains, look to me; I have enough confidence for all of us!"

As an investor myself, I am completely confident in the brainpower of the team, their determination, and their desire to see QXD succeed.

Here are two strategic advantages for QXD: 1. Quorum X Diagnostics is in the rapid diagnostic testing business; we are not just a COVID company and have other rapid test kits in the pipeline. 2. the QXD COVIDNOW test does have a unique proprietary technology (patent pending) that sets it apart from the competition as well as other unique features that we can capitalize on.

Therefore, do not fear. The QXD team is determined and ready. Let's Go!